Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

被引：2
作者：
Revuelta-Herrero, J. L. [1 ]
Gimenez-Manzorro, A. [1 ]
Matilla-Pena, A.
Herranz-Alonso, A. [1 ,2 ]
Sanjurjo-Saez, M. [1 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Pharm Dept, IiSGM, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Gastroenterol Dept, IiSGM, Madrid, Spain
来源：
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2018年 / 43卷 / 06期
关键词：
antiviral agents; drug interaction; hepatitis C; hepatocellular carcinoma; sorafenib; HEPATOCELLULAR-CARCINOMA; EVENTS; HCC;
D O I：
10.1111/jcpt.12727
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
What is known and objective No studies have evaluated the use of sorafenib with the direct-acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV). Case summaryWhat is new and conclusionThree hepatitis C virus genotype 1b-infected patients with well-preserved liver function were included in this prospective case series. The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV/PTV/r+DSV for 12weeks. One patient discontinued sorafenib while concomitant treatment due to grade 2 fatigue and muscular pain. The other two patients reported only grade 1 adverse effects. Sustained virologic response at 24weeks was achieved, and no tumour recurrences were found. The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective.
引用
收藏
页码：906 / 909
页数：4
相关论文
共 50 条
  • [11] Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration
    de Lorenzo-Pinto, A.
    Gimenez-Manzorro, A.
    Rodriguez-Gonzalez, C. G.
    Ahumada-Jimenez, A.
    Herranz-Alonso, A.
    Marzal-Alfaro, M. B.
    Sanjurjo-Saez, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (04) : 444 - 446
  • [12] Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma
    Zahariy Krastev
    Deian Jelev
    Krasimir Antonov
    Tanya Petkova
    Evelina Atanasova
    Nadezhda Zheleva
    Bojidar Tomov
    Yana Boyanova
    Lyudmila Mateva
    World Journal of Gastroenterology, 2016, (08) : 2630 - 2635
  • [13] Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection
    Cheng, Elaine Y.
    Saab, Sammy
    Holt, Curtis D.
    Busuttil, Ronald W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) : 2835 - 2848
  • [14] Safety Profile of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Hepatitis C in Romania: an Analysis Conducted in VigiBase®/WHO
    Cazacu, Irina
    Stroe, Roxana
    Dondera, Roxana
    Apan, Bogdan
    Farcas, Andreea
    Cristina, Anamaria
    Bucsa, Camelia
    Mogosan, Cristina
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2020, 29 (04) : 603 - 610
  • [15] Ombitasvir/paritaprevir/ritonavir + dasabuvir +/-ribavirin in real world hepatitis C patients
    Nicole Loo
    Eric Lawitz
    Naim Alkhouri
    Jennifer Wells
    Carmen Landaverde
    Angie Coste
    Rossalynn Salcido
    Michael Scott
    Fred Poordad
    World Journal of Gastroenterology, 2019, (18) : 2229 - 2239
  • [16] Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection
    Lucejko, Mariusz
    Parfieniuk-Kowerda, Anna
    Flisiak, Robert
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (08) : 1153 - 1164
  • [17] Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice
    Pineda, Juan A.
    Rivero-Juarez, Antonio
    de los Santos, Ignacio
    Collado, Antonio
    Merino, Dolores
    Morano-Amado, Luis E.
    Rios, Maria J.
    Perez-Perez, Montserrat
    Tellez, Francisco
    Palacios, Rosario
    Perez, Ana B.
    Mancebo, Maria
    Rivero, Antonio
    Macias, Juan
    HIV CLINICAL TRIALS, 2018, 19 (01): : 23 - 30
  • [18] Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
    Shiffman, Mitchell L.
    Rustgi, Vinod
    Bennett, Michael
    Forns, Xavier
    Asselah, Tarik
    Vila, Ramon Planas
    Liu, Li
    Pedrosa, Marcos
    Moller, Jonathan
    Reau, Nancy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (06) : 845 - 851
  • [19] Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection
    Deeks, Emma D.
    DRUGS, 2015, 75 (09) : 1027 - 1038
  • [20] Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs for Substance Abuse
    King, Jennifer R.
    Menon, Rajeev M.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (02): : 201 - 205
12345